Global Addictions Therapeutics Market Size By Type (Alcohol Addiction Therapeutics, Tobacco Addiction Therapeutics), By Application (Public, Private), By Region, And Segment Forecasts, 2023 to 2032

The Global Addictions Therapeutics Market was valued at USD 9.1 billion in 2023 and is projected to reach USD 18.6 billion by 2031, expanding at a CAGR of 9.3% during the forecast period. The market growth is primarily driven by the increasing prevalence of substance use disorders (SUDs), growing public awareness about addiction treatment options, and advancements in pharmacological therapies. Government initiatives to combat addiction and the rising demand for personalized treatment strategies are also accelerating market expansion.

Drivers:

1. Rising Incidence of Substance Use Disorders:

A steady increase in the misuse of alcohol, tobacco, prescription opioids, and illicit drugs has significantly contributed to the growing demand for addiction therapies worldwide.

2. Government and Institutional Support:

Robust initiatives by governments, non-profits, and healthcare institutions for addiction prevention and treatment—such as funding for rehabilitation centers and medication-assisted therapies (MAT)—are fueling market growth.

3. Technological and Drug Development Advancements:

Ongoing innovations in drug formulations, such as long-acting injectables and digital therapeutics for relapse prevention, are enhancing treatment effectiveness and adherence.

Restraints:

1. Social Stigma and Underreporting:

Despite rising awareness, the stigma associated with addiction leads to underreporting and reluctance to seek help, especially in developing countries.

2. Limited Access to Treatment in Low-Income Regions:

A lack of infrastructure and insufficient funding in many parts of the world hinders access to effective treatment options, limiting market penetration.

Opportunity:

1. Expansion in Telehealth and Remote Therapy:

Telemedicine and online counseling platforms are reshaping how addiction treatment is delivered, especially in rural or underserved communities.

2. Emerging Markets and Innovative Pipeline:

The rising focus on mental health and addiction treatment in Asia-Pacific and Latin America, coupled with a strong drug development pipeline, provides lucrative growth opportunities for market players.

Market by System Type Insights:

Based on therapy type, the medication-assisted treatment (MAT) segment dominated the market in 2023. MAT combines behavioral therapy and medications to treat substance use disorders, particularly opioid and alcohol addiction. Buprenorphine, methadone, and naltrexone are among the most commonly prescribed drugs, with increasing adoption due to high efficacy and reduced relapse rates.

Market by End-use Insights:

By end-use, the rehabilitation centers segment accounted for the largest market share in 2023. These centers are pivotal in offering structured treatment programs, including detoxification, behavioral counseling, and long-term relapse prevention. Meanwhile, hospitals and specialty clinics are anticipated to witness the fastest growth, driven by enhanced diagnosis and integration of addiction medicine into mainstream healthcare.

Market by Regional Insights:

In 2023, North America led the global addictions therapeutics market, fueled by a high incidence of opioid addiction, advanced healthcare systems, and supportive policies like the U.S. government's Opioid Crisis Response initiatives. Asia-Pacific is expected to be the fastest-growing region due to increasing awareness, improving healthcare access, and growing investments in mental health infrastructure.

Competitive Scenario:

Leading players in the global addictions therapeutics market include:

Alkermes plc

Indivior PLC

Pfizer Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Cipla Ltd.

Hikma Pharmaceuticals PLC

Omeros Corporation

BioCorRx Inc.

Camurus AB

These companies focus on R&D investments, regulatory approvals, partnerships, and the development of novel formulations (e.g., implantable treatments and injectables) to enhance treatment efficacy and patient adherence.

Scope of Work – Global Addictions Therapeutics Market

Key Market Developments:

2023: Indivior PLC launched a new sublingual film formulation of buprenorphine in Europe, aimed at improving patient compliance and ease of use.

2024: Camurus AB secured FDA approval for a once-monthly injectable formulation for opioid dependence, gaining strong adoption in the U.S. MAT market.

2025: BioCorRx Inc. announced a strategic partnership with a U.S.-based telehealth platform to expand digital addiction treatment offerings nationwide.

FAQs

1) What is the current market size of the Global Addictions Therapeutics Market?

The market was valued at USD 9.1 billion in 2023.

2) What is the major growth driver of the Global Addictions Therapeutics Market?

The rising prevalence of substance use disorders and increasing adoption of medication-assisted treatments are key drivers.

3) Which is the largest region during the forecast period in the Global Addictions Therapeutics Market?

North America is expected to remain the largest regional market due to high addiction rates and strong healthcare infrastructure.

4) Which segment accounted for the largest market share in Global Addictions Therapeutics Market?

The medication-assisted treatment (MAT) segment led the market in 2023.

5) Who are the key market players in the Global Addictions Therapeutics Market?

Key players include Alkermes, Indivior, Pfizer, Teva, Camurus, and BioCorRx.